Improving potencies and properties of CD4 down-modulating CADA analogs

Bibliography

• Choi H-J. Syntheses and properties of polycyclic triamines and application of ionophores to ion-selective electrodes. PhD Dissertation. State University of New York; Stony Brook: 1989
   Google Scholar
• Bell TW, Choi H-J, Harte W, Syntheses, conformations, and basicities of bicyclic triamines. J Am Chem Soc 2003;125:12196-210
   PubMed Web of Science ®Google Scholar
• Vermeire K, Zhang Y, Princen K, CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 2002;302:342-53
   PubMed Web of Science ®Google Scholar
• Ames MM, Reid JM. Analytical methods development and pharmacological studies with NSC D650760 (CADA). Technical Report N01-CM2779 1994, Task number five, month four
   Google Scholar
• Tseng C. Animal models of human viral diseases for evaluation of new therapeutic agents. Technical Report No1-AI-15100 1995
   Google Scholar
• Vermeire K, Bell TW, Choi H-J, The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharm 2003;63:203-10
   PubMed Web of Science ®Google Scholar
• Bell TW, Anugu S, Bailey P, Synthesis and structure-activity relationship studies of CD4 down-modulating cyclotriazadisulfonamide (CADA) analogues. J Med Chem 2006;49:1291-312
   PubMed Web of Science ®Google Scholar
• Vermeire K, Princen K, Hatse S, CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004;18:2115-25
   PubMed Web of Science ®Google Scholar
• Veiga AS, Santos NC, Castanho MARB. An insight on the leading HIV entry inhibitors. Recent Patents Anti-Infect Drug Disc 2006;1:67-73
   PubMedGoogle Scholar
• Este JA, Telenti A. HIV entry inhibitors. Lancet 2007;370:81-8
   PubMed Web of Science ®Google Scholar
• DeClercq E. The design of drugs for HIV and HCV. Nat Rev Drug Discov 2007;6:1001-18
   PubMed Web of Science ®Google Scholar
• Qian K, Morris-Natschke SL, Lee K-H. HIV entry inhibitors and their potential in HIV therapy. Med Res Rev 2009;29:369-93
   PubMed Web of Science ®Google Scholar
• Reimann KA, Khunkhun R, Lin W, A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002;18:747-55
   PubMed Web of Science ®Google Scholar
• Kuritzkes DR, Jacobsen J, Powderly WG, Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004;189:286-91
   PubMed Web of Science ®Google Scholar
• Schols D. HIV co-receptors as targets for antiviral therapy. Curr Top Med Chem 2004;4:883-93
   PubMed Web of Science ®Google Scholar
• Kazmierski WM, Gundmundsson KS, Piscitelli SC. Small molecule CCR5 and CXCR4-based viral entry inhibitors for ant-HIV therapy currently in development. In Annu Rep Med Chem 2007;42:301-20
   Web of Science ®Google Scholar
• Este JA. Inhibition of HIV entry. In: DeClercq E, editor. Antiviral Drug Strategies. Wiley-VCH; Weinheim: 2011. p. 29-50
   Google Scholar
• Vermeire K, Schols D, Bell TW. Inhibitors of HIV infection via the cellular CD4 receptor. Curr Med Chem 2006;13:763-71
   Google Scholar
• Nepom GT. Therapy of autoimmune diseases: clinical trials and new biologics. Curr Opin Immunol 2002;14:812-15
   PubMed Web of Science ®Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
   PubMed Web of Science ®Google Scholar
• Liu E, Moriyama H, Paronen J, Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J Autoimmun 2003;21:213-19
   PubMed Web of Science ®Google Scholar
• Hanns-Martin L. T-cell-activation inhibitors in rheumatoid arthritis. BioDrugs 2003;17:263-70
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655-62
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. The role of CD4 in T-cell activation: accessory molecule or co-receptor? Immunol Today 1989;10:234-8
   PubMedGoogle Scholar
• Ellmeier W, Sawada S, Littman DR. The regulation of CD4 and CD8 coreceptor gene expression during T cell development. Annu Rev Immunol 1999;17:523-54
   PubMed Web of Science ®Google Scholar
• Conti L, Varano B, Gauzzi MC, Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation. J Virol 2000;74:10207-11
   PubMed Web of Science ®Google Scholar
• Nokta MA, Li XD, Nichols J, Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals. AIDS Res Hum Retroviruses 2001;15:161-9
   Google Scholar
• Xiang J, McLinden JH, Rydze RA, Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells. J Immunol 2009;183:7860-9
   PubMed Web of Science ®Google Scholar
• Lisco A, Grivel JC, Biancotto A, Viral interactions in human lymphoid tissue: human herpesvirus 7 suppresses the replication of CCR5-tropic human immunodeficiency virus type 1 via CD4 modulation. J Virol 2007;81:708-17
   PubMed Web of Science ®Google Scholar
• Lama J. The physiological relevance of CD4 receptor down-modulation during HIV infection. Curr HIV Res 2003;1:167-84
   PubMedGoogle Scholar
• Ruiz A, Guatelli JC, Stephens EB. The Vpu protein: new concepts in virus release and CD4 down-modulation. Curr HIV Res 2010;8:240-52
   PubMed Web of Science ®Google Scholar
• Beaumier CM, Harris LD, Goldstein S, CD4 downregulation by memory CD4+ T cells in vivo renders African green monkeys resistant to progressive SIVagm infection. Nat Med 2009;15:879-85
   PubMed Web of Science ®Google Scholar
• Vermeire K, Schols D, Bell TW, Selective inhibition of CD4 protein translocation and cell surface expression as a novel tool for preventing HIV infection. Antivir J 2010;6(Supp 1):32
   Google Scholar
• Vermeire K, Schols D, Bell TW, A small-molecule inhibitor of CD4 protein translocation down-modulates the primary HIV receptor. Manuscript in preparation
   Google Scholar
• Garrison JL, Kunkel EJ, Hegde RS, A substrate-specific inhibitor of protein translocation into the endoplasmic reticulum. Nature 2005;436:287-9
   Google Scholar
• Besemer J, Harant H, Wang S, Selective inhibition of cotranslational translocation of vascular cell adhesion molecule. Nature 2005;436:290-3
   PubMed Web of Science ®Google Scholar
• Osborne AR, Rappoport TA, van den Berg B. Protein translocation by the Sec61/SecY channel. Annu Rev Cell Dev Biol 2005;21:529-50
   PubMed Web of Science ®Google Scholar
• Richman JE, Atkins TJ. Nitrogen analogs of crown ethers. J Am Chem Soc 1974;96:2268-70
   Web of Science ®Google Scholar
• Atkins TJ, Richman JE, Oettle WF. Macrocyclic polyamines: 1,4,7,10,13,16-hexaazacyclooctadecane. In: Org Synth Coll. Volume 6 Wiley; New York: 1988. p. 652-62
   Google Scholar
• Kerns EH, Di L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Academic Press; Burlington: 2008
   Google Scholar
• Vermeire K, Lisco A, Grivel J-C, Design and cellular kinetics of dansyl-labeled CADA derivatives with anti-HIV and CD4 receptor down-modulating activity. Biochem Pharmacol 2007;74:566-78
   PubMed Web of Science ®Google Scholar
• Demillo VG. Unsymmetrical cyclotriazadisulfonamide (CADA) compounds: synthesis and CD4 down-modulation potency. PhD Dissertation. University of Nevada; Reno: 2011
   Google Scholar
• Demillo VG, Goulinet-Mateo F, Kim J, Unsymmetrical cyclotriazadisulfonamide (CADA) compounds as human CD4 receptor down-modulating agents. J Med Chem 2011;54:5712-21
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
   Web of Science ®Google Scholar
• Kerns EH, Di L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Academic Press; Burlington: 2008. p. 103-21
   Google Scholar
• Diez-Torrubia A, Balzarini J, Andrei G, Dipeptidyl peptidase IV dependent water-soluble prodrugs of highly lipophilic bicyclic nucleoside analogues. J Med Chem 2011;54:1927-52
   PubMed Web of Science ®Google Scholar
• Scarbrough E, Vermeire K, Schols D, Synthesis of novel CADA analog prodrugs designed as down-modulators of the human CD4 Receptor. Antiviral Res 2011;90:A75-6
   Web of Science ®Google Scholar
• Veber DF, Johnson SP, Cheng H-Y, Molecular properties that influence oral bioavailability of drug candidates. J Med Chem 2002;45:2615-23
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem 2011;54:1539-54
   PubMed Web of Science ®Google Scholar